Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-044889
Filing Date
2025-05-16
Accepted
2025-05-16 16:12:57
Documents
54
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0241123-10q_denali.htm   iXBRL 10-Q 580212
2 CERTIFICATION ea024112301ex31-1_denali.htm EX-31.1 11447
3 CERTIFICATION ea024112301ex31-2_denali.htm EX-31.2 11487
4 CERTIFICATION ea024112301ex32-1_denali.htm EX-32.1 3845
5 CERTIFICATION ea024112301ex32-2_denali.htm EX-32.2 3923
  Complete submission text file 0001213900-25-044889.txt   4824995

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE deca-20250331.xsd EX-101.SCH 42201
7 XBRL CALCULATION FILE deca-20250331_cal.xml EX-101.CAL 17717
8 XBRL DEFINITION FILE deca-20250331_def.xml EX-101.DEF 241604
9 XBRL LABEL FILE deca-20250331_lab.xml EX-101.LAB 376105
10 XBRL PRESENTATION FILE deca-20250331_pre.xml EX-101.PRE 246133
57 EXTRACTED XBRL INSTANCE DOCUMENT ea0241123-10q_denali_htm.xml XML 454332
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41351 | Film No.: 25959370
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)